New Releases from NCBI BookshelfAlectinib for untreated ALK-positive advanced non-small-cell lung cancer.Alectinib for untreated ALK-positive advanced non-small-cell lung cancer.
Post Content
Uncategorized
New Releases from NCBI BookshelfOdevixibat (Bylvay): Indication: For the treatment of cholestatic pruritus in patients aged 12 months and older with Alagille syndrome (ALGS): Reimbursement Recommendation [Internet].Odevixibat (Bylvay): Indication: For the treatment of cholestatic pruritus in patients aged 12 months and older with Alagille syndrome (ALGS): Reimbursement Recommendation [Internet].
Canada’s Drug Agency (CDA-AMC) recommends that Bylvay be reimbursed by public drug plans for the treatment of cholestatic pruritus in
